Who are PIFLUFOLASTAT's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN, [Ga-68]PSMA, 18F-rhPSMA-7.3, piflufolastat (18F), 64Cu-SAR-bisPSMA, 68Ga-PSMA-11.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/piflufolastat.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

PIFLUFOLASTAT — Competitive Intelligence Brief

PIFLUFOLASTAT (PIFLUFOLASTAT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radioactive Diagnostic Agent [EPC].

marketed Radioactive Diagnostic Agent [EPC] PSMA Small molecule Live · refreshed every 30 min

Target snapshot

PIFLUFOLASTAT (PIFLUFOLASTAT). Piflufolastat F 18 binds to PSMA-expressing cells, including prostate cancer cells, and emits positrons for imaging.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PIFLUFOLASTAT TARGET	PIFLUFOLASTAT		marketed	Radioactive Diagnostic Agent [EPC]	PSMA	2021-01-01
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN	LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN		marketed	Radioligand Therapeutic Agent [EPC]	PSMA	2022-01-01
[Ga-68]PSMA	[Ga-68]PSMA	Norbert Avril, M.D.	marketed	PET imaging agent / radiopharmaceutical	PSMA (prostate-specific membrane antigen)
18F-rhPSMA-7.3	18F-rhPSMA-7.3	Hackensack Meridian Health	marketed	PET imaging agent / radiopharmaceutical	PSMA (prostate-specific membrane antigen)
piflufolastat (18F)	piflufolastat (18F)	Blue Earth Diagnostics	marketed	PSMA-targeting PET imaging agent	PSMA (prostate-specific membrane antigen)
64Cu-SAR-bisPSMA	64Cu-SAR-bisPSMA	Clarity Pharmaceuticals Ltd	phase 3	Radiopharmaceutical; PET imaging agent	PSMA (prostate-specific membrane antigen)
68Ga-PSMA-11	68Ga-PSMA-11	Weill Medical College of Cornell University	phase 3	PET imaging agent / radiopharmaceutical	PSMA (prostate-specific membrane antigen)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radioactive Diagnostic Agent [EPC] class)

· 6 drugs in this class
GE HealthCare · 3 drugs in this class
Blue Earth · 2 drugs in this class
Avid Radiopharms Inc · 2 drugs in this class
Ge Hlthcare Inc · 2 drugs in this class
Ge Healthcare · 1 drug in this class
Ge Hlthcare · 1 drug in this class
Lantheus Medical Imaging · 1 drug in this class
Life Molecular · 1 drug in this class
Mcprf · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PIFLUFOLASTAT — Competitive Intelligence Brief. https://druglandscape.com/ci/piflufolastat. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab